2022-502994-40-00招募中2 期
J3P-MC-FTAF: An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 62
- 试验地点
- 29
- 主要终点
- Phase 2a: Change from Baseline in Disease Activity Score – high-sensitivity C-reactive protein (DAS28-hsCRP)
研究概览
简要总结
Phase 2a: To evaluate the efficacy of LY3871801 compared to placebo as measured by changes in DAS28-hsCRP
Phase 2b: To evaluate the efficacy of LY3871801 compared to placebo in achieving ACR50
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Have a diagnosis of adult onset rheumatoid arthritis for at least 3 months
排除标准
- •Had cancer within the last 5 years, except for some types of skin cancer or cervical cancer
- •Had certain types of infections within the last 3 months
- •Have current hepatitis virus B or C infection
结局指标
主要结局
Phase 2a: Change from Baseline in Disease Activity Score – high-sensitivity C-reactive protein (DAS28-hsCRP)
Phase 2a: Change from Baseline in Disease Activity Score – high-sensitivity C-reactive protein (DAS28-hsCRP)
Phase 2b: Percentage of Participants Achieving American College of Rheumatology (ACR)50
Phase 2b: Percentage of Participants Achieving American College of Rheumatology (ACR)50
次要结局
未报告次要终点
研究者
Lilly Clinical Trials information desk
Scientific
Eli Lilly & Co.
研究点 (29)
Loading locations...
相似试验
招募中
2 期
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative ColitisUlcerative Colitis2023-504673-20-00Janssen - Cilag International102
招募中
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic PainNCT07285018Eli Lilly and Company150
招募中
2 期
A Study of LY3457263 Compared to Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideType 2 Diabetes2024-520328-27-00Eli Lilly & Co.20
招募中
2 期
A Phase 2 Randomized Trial Evaluating Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mass (ARTEMIS)Postmenopausal Osteoporosis2024-515610-41-00Angitia Inc. Ltd.260
招募中
3 期
Study of efficacy and safety of LNP023 in primary IgA nephropathy patients.2024-511067-29-00Novartis Pharma AG102